Login | Users Online: 279  
Home Print this page Email this page Small font sizeDefault font sizeIncrease font size   
Home | About us | Editorial board | Search | Ahead of print | Current Issue | Archives | Submit article | Instructions | Subscribe | Advertise | Contact us
Year : 2022  |  Volume : 23  |  Issue : 1  |  Page : 1-9

Transcatheter aortic valve implantation for degenerated surgical aortic bioprosthesis: A systematic review

1 Department of Cardiovascular Diseases, Mayo Clinic, Jacksonville, Florida, USA
2 Department of Adult Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar
3 Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA

Correspondence Address:
Dr. Mayra Guerrero
Department of Cardiovascular Diseases, Mayo Clinic, 200 First St Sw, Rochester, Minnesota 55905
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/heartviews.heartviews_25_22

Rights and Permissions

Background: Transcatheter aortic valve in valve (Aviv) replacement has been shown to be an effective therapeutic option in patients with failed aortic bioprosthetic valves. This review intended to evaluate contemporary 1-year outcomes of Aviv in recent studies. Methods: A systematic review on outcomes of Aviv was performed using the best available evidence from studies obtained using a MEDLINE, Cochrane database, and SCOPUS search. Endpoints of interest were survival, coronary artery obstruction, prosthesis-patient mismatch (PPM), stroke, pacemaker implantation, and structural valve deterioration. Results: A total of 3339 patients from 23 studies were included. Mean age was 68–80 years, 20%–50% were female, and Society of Thoracic Surgeons score ranged from 5.7 to 31.1. Thirty-day all-cause mortality ranged from 2% to 8%, and 1-year all-cause mortality ranged from 8% to 33%. Coronary artery obstruction risk after Aviv ranged from 0.6% to 4%. One-year stroke ranged from 2% to 8%. Moderate-severe PPM occurred in 11%–58%, and pacemaker rate at 1 year ranged from 5% to 12%. Conclusion: Transcatheter aortic ViV has emerged as an effective therapeutic option to treat patients with failed bioprostheses. The acceptable complication rate and favorable 1-year outcomes make Aviv an appropriate alternative to redo surgical aortic valve replacement.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded75    
    Comments [Add]    

Recommend this journal